小線源治療の世界市場

◆英語タイトル:Global Brachytherapy Industry

Global Industry Analystsが発行した調査報告書(GIA21AP035)◆商品コード:GIA21AP035
◆発行会社(リサーチ会社):Global Industry Analysts
◆発行日:2021年4月
◆ページ数:266
◆レポート形式:英語 / PDF(印刷不可)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,600 ⇒換算¥828,800見積依頼/購入/質問フォーム
Five UserUSD7,840 ⇒換算¥1,160,320見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Brachytherapy Market to Reach $413.7 Million by 2027- Amid the COVID-19 crisis, the global market for Brachytherapy estimated at US$330 Million in the year 2020, is projected to reach a revised size of US$413.7 Million by 2027, growing at aCAGR of 3.3% over the period 2020-2027. High Dose Rate, one of the segments analyzed in the report, is projected to record 3.5% CAGR and reach US$241.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Low Dose Rate segment is readjusted to a revised 2.9% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $89.1 Million, While China is Forecast to Grow at 6% CAGR
- The Brachytherapy market in the U.S. is estimated at US$89.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$85.8 Million by the year 2027 trailing a CAGR of 6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.9% and 2.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

- Select Competitors (Total 29 Featured) -
Bard Medical Division
Best Medical International, Inc.
Best Vascular, Inc.
Boston Scientific Corporation
Carl Zeiss Meditec AG
Elekta AB
Sirtex Medical Limited
Sun Nuclear Corporation
Theragenics Corporation
Varian Medical Systems, Inc.
Xoft, Inc.

❖ レポートの目次 ❖

I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Brachytherapy – A Prelude
Technological Advances to Boost Brachytherapy Uptake
Recent Market Activity
Growing Cancer Cases in Developing Countries Bode Well for the Brachytherapy Market
Cost Effectiveness – A Major Benefit of Brachytherapy
Competitive Landscape – An Overview
Key Market Statistics
The US Leads the Brachytherapy Devices Market Developing Regions to Spearhead Growth
Brachytherapy Provides More Hope for Cancer Patients, Compared to EBRT
Comparison of Brachytherapy Over EBRT in Prostate Cancer Treatment
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increase in Diagnosed Cases of Cancer – A Major Growth Driver
Cancer Prone Sites based on Age
Ballooning Global Population Offers Significant Growth Opportunities
Rising Healthcare Needs of Aging Global Population Drives Brachytherapy
Increasing Healthcare Spending in Emerging Markets
Scientific Evidence Continues to Support Brachytherapy in Prostate Cancer Treatment
Macular Degeneration – An Emerging Brachytherapy Application
APBI Therapy Rise in Popularity
IORT: Attractive Alternative to Traditional Radiation Treatment
Balloon Brachytherapy Gains Prominence
Growing Prominence of Imaging Techniques in Brachytherapy
Radiosensitizers – An Emerging Option to Improve Dose Delivery
Radiation Safety – An Important Issue in Brachytherapy Treatment
Residency Training on Brachytherapy – A Way to Improve Clinical Use
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Current & Future Analysis for Brachytherapy by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Brachytherapy by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Brachytherapy by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
TABLE 4: World Current & Future Analysis for High Dose Rate by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for High Dose Rate by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for High Dose Rate by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 7: World Current & Future Analysis for Low Dose Rate by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Low Dose Rate by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Low Dose Rate by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 10: World Current & Future Analysis for Prostate Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Prostate Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Prostate Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 13: World Current & Future Analysis for Gynecological Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Gynecological Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Gynecological Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 16: World Current & Future Analysis for Breast Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Breast Cancer by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Breast Cancer by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 19: World Current & Future Analysis for Other Applications by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Other Applications by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Other Applications by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 22: USA Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 23: USA Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: USA 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 25: USA Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 26: USA Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: USA 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
CANADA
TABLE 28: Canada Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 29: Canada Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: Canada 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 31: Canada Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 32: Canada Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: Canada 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
JAPAN
TABLE 34: Japan Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 35: Japan Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: Japan 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 37: Japan Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: Japan Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: Japan 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
CHINA
TABLE 40: China Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: China Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 42: China 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 43: China Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: China Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 45: China 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
EUROPE
TABLE 46: Europe Current & Future Analysis for Brachytherapy by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 47: Europe Historic Review for Brachytherapy by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 48: Europe 15-Year Perspective for Brachytherapy by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
TABLE 49: Europe Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Europe Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 51: Europe 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 52: Europe Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Europe Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 54: Europe 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
FRANCE
TABLE 55: France Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: France Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 57: France 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 58: France Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: France Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 60: France 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
GERMANY
TABLE 61: Germany Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: Germany Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 63: Germany 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 64: Germany Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: Germany Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 66: Germany 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
ITALY
TABLE 67: Italy Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: Italy Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 69: Italy 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 70: Italy Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 71: Italy Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 72: Italy 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
UNITED KINGDOM
TABLE 73: UK Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: UK Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 75: UK 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 76: UK Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: UK Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 78: UK 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
SPAIN
TABLE 79: Spain Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Spain Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 81: Spain 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 82: Spain Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: Spain Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 84: Spain 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
RUSSIA
TABLE 85: Russia Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: Russia Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 87: Russia 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 88: Russia Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 89: Russia Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 90: Russia 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
REST OF EUROPE
TABLE 91: Rest of Europe Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: Rest of Europe Historic Review for Brachytherapy by Type – High Dose Rate and Low Dose Rate Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 93: Rest of Europe 15-Year Perspective for Brachytherapy by Type – Percentage Breakdown of Value Sales for High Dose Rate and Low Dose Rate for the Years 2012, 2020 & 2027
TABLE 94: Rest of Europe Current & Future Analysis for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 95: Rest of Europe Historic Review for Brachytherapy by Application – Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 96: Rest of Europe 15-Year Perspective for Brachytherapy by Application – Percentage Breakdown of Value Sales for Prostate Cancer, Gynecological Cancer, Breast Cancer and Other Applications for the Years 2012, 2020 & 2027
ASIA-PACIFIC
TABLE 97: Asia-Pacific Current & Future Analysis for Brachytherapy by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 98: Asia-Pacific Historic Review for Brachytherapy by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 99: Asia-Pacific 15-Year Perspective for Brachytherapy by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
TABLE 100: Asia-Pacific Current & Future Analysis for Brachytherapy by Type – High Dose Rate and Low Dose Rate – Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 小線源治療の世界市場(Global Brachytherapy Industry)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆